Physician profile
Russell D Yang
NPI 1518993229
$244,288.39
in general payments reported to CMS, 2019-2025
29 companies · $61K in 2025
The $61K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $13K · 2021: $30K · 2022: $45K · 2023: $47K · 2024: $46K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $123K · Travel and Lodging: $19K · Food and Beverage: $12K · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $123,350.26 |
| Travel and Lodging | $18,904.29 |
| Food and Beverage | $12,246.74 |
| Education | $151.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $223,959.33 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Boston Scientific Corporation | $6,639.61 | 2019-2025 | Orise, Overstitch Nxt Endoscopic Suturing System, Exalt Model D |
| Allergan, INC. | $6,414.85 | 2019-2020 | |
| Gilead Sciences, INC. | $2,400.51 | 2019-2025 | Vemlidy |
| Pfizer INC. | $1,257.44 | 2019-2025 | |
| Janssen Biotech, INC. | $526.55 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $479.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $391.91 | 2019-2025 | Entyvio, Eohilia |
| Covidien Lp | $292.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $282.30 | 2022-2025 | Dupixent |
| Kowa Pharmaceuticals America, INC. | $252.24 | 2022-2023 | Seglentis |
| Ironwood Pharmaceuticals, INC | $232.69 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $201.67 | 2025 | Tremfya |
| Echosens North America, INC. | $160.75 | 2024-2025 | Fibroscan, Fibroscan |
| Cook Medical LLC | $133.96 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $124.29 | 2024-2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $108.72 | 2020-2022 | |
| Genzyme Corporation | $84.10 | 2022-2025 | |
| Ardelyx, INC. | $70.72 | 2024 | Ibsrela |
| Celgene Corporation | $56.81 | 2022-2023 | Zeposia |
| Novartis Pharmaceuticals Corporation | $48.50 | 2019 | |
| Novo Nordisk INC | $39.40 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $30.83 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.70 | 2020 | |
| Intercept Pharmaceuticals, INC. | $21.06 | 2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $19.18 | 2024 | |
| Amarin Pharma, INC. | $18.18 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $12.72 | 2021 | |
| Erbe USA INC | $4.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.